Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01073293
Other study ID # V503-007
Secondary ID 2010_512
Status Completed
Phase Phase 3
First received
Last updated
Start date April 22, 2010
Est. completion date June 16, 2011

Study information

Verified date October 2018
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate whether co-administration of the first dose of V503 and REPEVAX™ is well tolerated and causes a non-inferior immune response when compared to administration of REPEVAX™ one month following the first dose of V503.


Recruitment information / eligibility

Status Completed
Enrollment 1054
Est. completion date June 16, 2011
Est. primary completion date June 16, 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Years to 15 Years
Eligibility Inclusion criteria:

- Participant is in good health

- Participant's parent/legal guardian can read, understand, and complete the vaccination report card

- Participant is not sexually active and does not plan on becoming sexually active during the study

- Participant has received a documented full primary immunization series against diphtheria, tetanus, pertussis, and poliovirus (inactivated and/or oral poliovirus), but not in the last 5 years. There must be a 5-year interval from a prior vaccination containing any one of these vaccine antigens.

Exclusion Criteria:

- Participant has a known allergy to any vaccine component of V503 or REPEVAX™

- Participant has had a severe reaction affecting the brain (e.g., evolving encephalopathy) within 7 days after a previous dose of a pertussis-containing vaccine

- Participant has had a progressive severe illness affecting the brain after a previous dose of tetanus, diphtheria, poliovirus or a component pertussis combination (acellular and whole cell) vaccine

- Participant ever had Guillain-Barré syndrome or brachial neuritis following a previous dose of a tetanus-containing vaccine

- Participant has a condition that is a contraindication to vaccination as indicated in the most up to date package inserts of REPEVAX™

- Participant has a history of severe allergic reaction that required medical intervention

- Participant has hemophilia, thrombocytopenia, is receiving anticoagulation therapy and/or has any coagulation disorder that would contraindicate intramuscular injections

- Participant is concurrently enrolled in clinical studies of investigational agents

- Female participant is pregnant

- Participant has donated blood within 1 week prior to first study vaccination, or intends to donate during the study

- Participant is immunocompromised, immunodeficient, or has an autoimmune condition

- Participant has had a splenectomy

- Participant has received immunosuppressive therapies in the prior year

- Participant has received immune globulin product or blood-derived product in the last 3 months

- Participant has received inactivated vaccine(s) within 14 days or live vaccine(s) within 21 days of first study vaccination

- Participant has received a marketed HPV vaccine or has participated in an HPV vaccine trial

- Participant has received a tetanus, diphtheria, pertussis, or poliovirus (inactivated and/or oral poliovirus) vaccination within the last 5 years

- Participant has a fever =100°F within 24 hours of vaccination

- Participant has any history or current condition, therapy, lab abnormality, or other circumstance such that it is not in the best interest of the participant to participate

- Participant and parent/legal guardian are unable to give assent/consent

- Participant is unlikely to adhere to the study procedures or is planning to relocate during the study

- Participant has recent history of illicit drug or alcohol abuse

- Participant has a history of HPV

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
V503 Vaccine
V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
REPEVAX™ (Concomitant)
REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
REPEVAX™ (Non-concomitant)
REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (2)

Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, Joura EA, Ciprero K, Maansson R, Luxembourg A, Sobanjo-ter Meulen A. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, teta — View Citation

Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safe — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured using a competitive Luminex immunoassay. Titers are reported in milli Merck Units/mL. 4 weeks following Month 6 vaccination
Primary Percentage of Participants With a V503 Injection-site Adverse Experience An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received V503 vaccination were reported for this endpoint. Day 1 through Day 5 following Day 1 vaccination
Primary Percentage of Participants With a Repevax™ Injection-site Adverse Experience For the Concomitant Vaccination group, injection-site AEs are reported following Day 1 vaccination; for the Non-concomitant Vaccination group, injection-site AEs are reported following Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received Repevax™ vaccination were reported for this endpoint. Day 1 through Day 5 following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination
Primary Percentage of Participants With Maximum Temperature >=37.8 °C (>=100.0 °F) (Oral or Oral Equivalent) For the Concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 vaccination. Up to 5 days following the Day 1 and Month 1 vaccination / visit
Primary Percentage of Participants With a Systemic Adverse Experience For the Concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body that is temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an adverse experience. A systemic AE was an AE that was not associated with the injection site. Up to 15 days following the Day 1 and Month 1 vaccination / visit
Primary Percentage of Participants Who Achieve Acceptable Titers of Anti-Diphtheria and Anti-Tetanus Antibody For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to diphtheria toxin were measured using a cell-based Diphtheria Micrometabolic Inhibition assay. Serum titers of neutralizing antibody to tetanus toxin were measured using an enzyme immunoassay. The lower limits of quantitation of the assays was 0.01 International Units (IU)/mL and 0.04 IU/mL, respectively. Acceptable titers refer to the World Health Organization-defined protective titer of >=0.1 IU/mL. 4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination
Primary Geometric Mean Titers of Pertussis Antibody Responses For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), anti-pertactin (PRN), and anti-fimbriae 2/3 (FM 2/3) antibodies were measured using enzyme-linked immunosorbent assays. Titers are expressed as enzyme-linked immunoassay units/mL (ELU/mL). 4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination
Primary Percentage of Participants Who Achieve Acceptable Titers of Anti-Poliovirus Antibody For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to poliovirus type 1, 2, and 3 were measured using a microneutralization assay. Serial dilutions of sera were incubated with type-specific standard poliovirus and sensitive cells. Neutralization of the virus was measured by cell staining. Acceptable titers were defined as neutralization at >=1:8 dilution of serum. 4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination
Secondary Percentage of Participants Who Seroconvert for Each of the HPV Types Blood was drawn at Month 7 and assayed to determine whether or not a participant had achieved seroconversion for the HPV types. The lower limit of the titer (milli Merck U/mL) considered seropositive was as follows: HPV Type 6: >=30, HPV Type 11: >=16; HPV Type 16: >=20, HPV Type 18: >=24, HPV Type 31: >=10, HPV Type 33: >=8, HPV Type 45: >=8, HPV Type 52: >=8, and HPV Type 58: >=8. Month 7
See also
  Status Clinical Trial Phase
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Active, not recruiting NCT05580341 - Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Phase 3
Completed NCT06399341 - Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
Recruiting NCT03548740 - Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Completed NCT00092547 - A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Phase 3
Completed NCT00157950 - Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Phase 3
Recruiting NCT00365729 - Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men N/A
Completed NCT03584308 - Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Phase 2
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Completed NCT00549250 - Human Papillomavirus 6/11 in the Lower Airway of Neonates N/A
Recruiting NCT04694495 - HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Completed NCT06439433 - ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection Phase 2
Completed NCT00380367 - Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Phase 3
Completed NCT01894425 - Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation N/A
Completed NCT00685412 - Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 Phase 1
Completed NCT00365716 - Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Phase 2
Completed NCT04772534 - Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) Phase 3
Completed NCT05119855 - Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) Phase 3
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2